cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1317Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАCORONARY HEART DISEASEВлияние реваскуляризации миокарда на динамику сосудистого эндотелиального и трансформирующего факторов роста у больных ишемической болезнью сердцаMyocardial revascularization effects on vascular endothelial growth factor and transforming growth factor β-1 in coronary heart disease patientsСергиенкоИ. В.SergienkoI. V.igor@cardioline.ruСемёноваА. Е.SemenovaA. E.igor@cardioline.ruМасенкоВ. П.MasenkoV. P.igor@cardioline.ruХабибуллинаЛ. И.HabibullinaL. I.igor@cardioline.ruГабрусенкоС. А.GabrusenkoS. A.igor@cardioline.ruКухарчукВ. В.KukharchukV. V.igor@cardioline.ruБеленковЮ. Н.BelenkovYu. N.igor@cardioline.ruФГУ «Российский кардиологический научно-производственный комплекс Росздрава», МоскваРоссияRussian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, MoscowRussian Federation200720102007651217Copyright © Сергиенко И.В., Семёнова А.Е., Масенко В.П., Хабибуллина Л.И., Габрусенко С.А., Кухарчук В.В., Беленков Ю.Н., 20072007Сергиенко И.В., Семёнова А.Е., Масенко В.П., Хабибуллина Л.И., Габрусенко С.А., Кухарчук В.В., Беленков Ю.Н.Sergienko I.V., Semenova A.E., Masenko V.P., Habibullina L.I., Gabrusenko S.A., Kukharchuk V.V., Belenkov Y.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1317

Цель. Изучить динамику сосудистого эндотелиального фактора роста (VEGF), трансформирующего фактора роста-β1 (TGF-β1) и рецепторов сосудистого эндотелиального фактора роста (sVEGF-R1) у больных ишемической болезнью сердца (ИБС) до и после реваскуляризации. Материал и методы. Основную группу составили 40 больных ИБС, которым была выполнена транслюминальная баллонная коронарная ангиопластика (ТБКА) – 75% или операция коронарного шунтирования (КШ) – 25%. В группу контроля включены 30 здоровых добровольцев. Забор крови осуществлялся натощак за сутки и через 6 дней после реваскуляризации, а у здоровых добровольцев однократно натощак. Результаты. У больных основной группы базальный уровень VEGF (в покое) достоверно не отличался от уровня VEGF у здоровых добровольцев – 192,4±166,1 пг/мл и 166,9±96,9 пг/мл соответственно (р=0,4); выявлено достоверное различие между базальным уровнем TGF в основной (11±4,9 пг/мл) и контрольной (120±32,4 пг/мл) группах (р<0,0001). Содержание sVEGF-R1 в обеих группах было на уровне чувствительности метода, растворимые рецепторы к VEGF практически отсутствовали в крови здоровых добровольцев и больных ИБС – sVEGF-R1. Через 6 дней после реваскуляризации достоверно увеличилась концентрация VEGF – базальный уровень составил 192,4±166,1 пг/мл, после реваскуляризации – 264,7±226,6 пг/мл (р=0,066). Однако достоверные изменения в содержании TGF и sVEGF-R1 отсутствовали. Во всех остальных случаях имело место достоверное повышение VEGF после реваскуляризации, что обусловлено транзиторной ишемией миокарда, вызванной процедурой реваскуляризации. Заключение. Ишемия миокарда приводит к повышению содержания VEGF и понижению TGF. На концентрацию sVEGF-R1 ишемия миокарда значимого влияния не оказывает.

Aim. To assess the dynamics of vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF- 1) and VEGF receptor Flt-1 (sFlt-1 or sVEGF-R1) levels in coronary heart disease (CHD) patients before and after myocardial revascularization. Material and methods: We examined fasting serum VEGF, TGF-β1 and sVEGF-R1 concentrations in 40 CHD patients (main group) 1 day before and 6 days after successful myocardial revascularization (percutaneous coronary intervention, PCI – 75%; grafting bypass surgery – 25%). Control group included 30 healthy volunteers, with fasting blood samples taken once. Results: Serum levels of VEGF and TGF-β1 in controls were 166,9±96,9 and 120±32,4 pg/ml, respectively. Before myocardial revascularization in CHD patients, VEGF level was 192,4±166,1 pg/ml, and TGF-β1 level was 11±4,9 pg/ml. There was no significant difference in basic serum levels of VEGF (p=0,4), but TGF-β1 levels were significantly lower in CHD patients, comparing to controls (р<0,0001). sVEGF-R1 levels were very low in main (0,3 pg/ml) and control (0,2 pg/ml) groups (р>0,05). After myocardial revascularization, the levels of VEGF, TGF-β1 and sVEGF-R1 were 264,7±226,6, 11,7±4,9, and 0,2 pg/ml, respectively. There was a significant increase in VEGF levels (р=0,066), without any substantial changes in TGF-β1 (р>0,05) and sVEGF-R1 (р>0,05) levels 6 days after revascularization. VEGF level reduction was observed in 6 out of 30 (20%) patients after PCI and in 2 out of 10 (20%) patients after grafting bypass surgery. In the other cases, post5revascularization VEGF level increased significantly, due to intra-revascularization transient myocardial ischemia. Conclusion: Myocardial ischemia increased VEGF levels and decreased TGF-β1 levels, not affecting sVEGF-R1 concentration.

сосудистый эндотелиальный фактор ростатрансформирующий фактор роста-β1ишемия миокардареваскуляризация миокардаишемическая болезнь сердцаvascular endothelial growth factortransforming growth factor-beta1myocardial ischemiamyocardial revascularizationcoronary heart diseaseReferencesAmerican Heart Association. Heart Disease and Stroke Statistics – 2005 Update. Dallas, Tex: American Heart Association; 2004.American Heart Association. Heart Disease and Stroke Statistics – 2005 Update. Dallas, Tex: American Heart Association; 2004.Annexal BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005; 65: 649-55.Annexal BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 2005; 65: 649-55.Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21.Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21.Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001; 188: 359-68.Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001; 188: 359-68.Roberts AB, Anzano MA, Lamb LC, et al. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature 1982; 295: 417-9.Roberts AB, Anzano MA, Lamb LC, et al. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature 1982; 295: 417-9.Massague J. Type beta transforming growth factor from feline sarcoma virus-transformed rat cells. Isolation and biological properties. J Biol Chem 1984; 259: 9756-61.Massague J. Type beta transforming growth factor from feline sarcoma virus-transformed rat cells. Isolation and biological properties. J Biol Chem 1984; 259: 9756-61.Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.Ruwhof C, van Wamel AE, Egas JM, van der Laarse A. Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem 2000; 208: 89-98.Ruwhof C, van Wamel AE, Egas JM, van der Laarse A. Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. Mol Cell Biochem 2000; 208: 89-98.Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004; 64: 526-35.Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004; 64: 526-35.Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71.Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-71.Stefoni S, Cianciolo G, Donati G, et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61(1): 324-35.Stefoni S, Cianciolo G, Donati G, et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61(1): 324-35.Yin R, Feng J, Chen D, Wu H. Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction. Chin Med Sci J 2000; 15(4): 205-9.Yin R, Feng J, Chen D, Wu H. Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction. Chin Med Sci J 2000; 15(4): 205-9.-. Soeki T, Tamura Y, Shinohara H, et al. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 2000; 93(3): 168-74.-. Soeki T, Tamura Y, Shinohara H, et al. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 2000; 93(3): 168-74.Ogawa H, Suefuji H, Soejima H, et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 2000; 93(1-2): 93-9.Ogawa H, Suefuji H, Soejima H, et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 2000; 93(1-2): 93-9.Kranz A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 2000; 32(1): 65-72.Kranz A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 2000; 32(1): 65-72.Denizot Y, Guglielmi L, Cornu E, Nathan N. Alterations in plasma angiogenic growth factor concentrations after coronary artery bypass graft surgery: relationships with post-operative complications. Cytokine 2003; 24(1-2): 7-12.Denizot Y, Guglielmi L, Cornu E, Nathan N. Alterations in plasma angiogenic growth factor concentrations after coronary artery bypass graft surgery: relationships with post-operative complications. Cytokine 2003; 24(1-2): 7-12.Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. JACC 2000; 35(4): 968-73.Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. JACC 2000; 35(4): 968-73.Nakajima K, Tabata S, Yamashita T, et al. Plasma vascular endothelial growth factor level is elevated in patients with multi-vessel coronary artery disease. Clin Cardiol 2004; 27(5): 281-6.Nakajima K, Tabata S, Yamashita T, et al. Plasma vascular endothelial growth factor level is elevated in patients with multi-vessel coronary artery disease. Clin Cardiol 2004; 27(5): 281-6.Chung NA, Lydakis C, Belgore F, et al. Angiogenesis, thrombo-genesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 2003; 89(12): 1411-5.Chung NA, Lydakis C, Belgore F, et al. Angiogenesis, thrombo-genesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 2003; 89(12): 1411-5.Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003; 104(4): 397-404.Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003; 104(4): 397-404.Suzuki H, Murakami M, Shoji M, et al. Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease. Coron Artery Dis 2003; 14(4): 301-7.Suzuki H, Murakami M, Shoji M, et al. Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease. Coron Artery Dis 2003; 14(4): 301-7.Forsythe JA, Bing-Hua Jlang, Iyer NV, et al. Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1. Mol Сell biol 1996; 16(9): 4604-13.Forsythe JA, Bing-Hua Jlang, Iyer NV, et al. Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1. Mol Сell biol 1996; 16(9): 4604-13.-. Sung KC, Kim KS, Lee S. Hypoxic regulation of VEGF, HIF-1(alpha) in coronary collaterals development. Korean J Intern Med 2005; 20(4): 295-302.-. Sung KC, Kim KS, Lee S. Hypoxic regulation of VEGF, HIF-1(alpha) in coronary collaterals development. Korean J Intern Med 2005; 20(4): 295-302.Sim EK, Zhang L, Shim WS, et al. Therapeutic angiogenesis for coronary artery disease. J Card Surg 2002; 17(4): 350-4.Sim EK, Zhang L, Shim WS, et al. Therapeutic angiogenesis for coronary artery disease. J Card Surg 2002; 17(4): 350-4.Angiogenic Gene Therapy 3 Trial — Intracoronary Administration of Ad.FGF-4 in Patients With Stable Angina — 1-Year Results. American College of Cardiology 2005 Annual Scientific SessionLuis Gruberg, MD, FACC. AGENT 3.Angiogenic Gene Therapy 3 Trial — Intracoronary Administration of Ad.FGF-4 in Patients With Stable Angina — 1-Year Results. American College of Cardiology 2005 Annual Scientific SessionLuis Gruberg, MD, FACC. AGENT 3.Габрусенко С.А., Малахов В.В., Сергиенко И.В. и др. Первый опыт применения в России лечебного метода наружной контрпульсации у больных ишемической болезнью сердца Тер архив 2006; 9: 27-33.Габрусенко С.А., Малахов В.В., Сергиенко И.В. и др. Первый опыт применения в России лечебного метода наружной контрпульсации у больных ишемической болезнью сердца Тер архив 2006; 9: 27-33.Gerrah R, Fogel M, Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol 2004; 94(1): 25-9.Gerrah R, Fogel M, Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol 2004; 94(1): 25-9.Voisine P, Bianchi C, Ruel M, et al, Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor Surgery 2004; 136(2): 407-15.Voisine P, Bianchi C, Ruel M, et al, Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor Surgery 2004; 136(2): 407-15.Giurgea AG, Margeta C, Maca T, et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol 2006; 47(1): 30-6.Giurgea AG, Margeta C, Maca T, et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol 2006; 47(1): 30-6.

The authors declare that there are no conflicts of interest present.